Andreas Lennartsson
Acute myeloid leukemia (AML) has a poor prognosis in both adults and children, with a long-term survival of only 25% and 60% respectively. No major development has occurred of the treatment since, the last decades and the majority of treatments for AML consist of cytotoxic drugs with low specificity.
Comparte este artículo
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 